Shared insight on the clinical impact circulating tumor DNA testing has had on the management of patients with breast cancer.
EP. 1: An Overview of Minimal Residual Disease (MRD) Testing
Expert oncologist Aditya Bardia, MD, MPH, provides a broad overview of minimal residual disease testing across a number of tumor types and clinical settings.
EP. 2: Applications of ctDNA Assessment in Early Breast Cancer
Barry Rosen, MD, provides an overview of circulating tumor DNA’s role in early stage breast cancer detection and management.
EP. 3: Applications of ctDNA Assessment in Metastatic Breast Cancer and Relapse
Aditya Bardia, MD, MPH, shares insight on how circulating tumor DNA is used in metastatic breast cancer and relapse detection.
EP. 4: Role of ctDNA in the Neoadjuvant Setting of Breast Cancer
Expert perspectives on the value of circulating tumor DNA in the neoadjuvant setting of breast cancer management.
EP. 5: Role of ctDNA in the Adjuvant Setting of Breast Cancer
Aditya Bardia, MD, MPH, and Barry Rosen, MD, discuss the role of circulating tumor DNA in the adjuvant setting of breast cancer.
EP. 6: ctDNA in Breast Cancer: Cancer Detection Vs Therapy Selection
A brief synopsis on the use of circulating tumor DNA for cancer detection versus treatment selection in breast cancer management.
EP. 7: Other Clinical Studies on ctDNA Use in Breast Cancer
Shared insight on how clinical trial data behind circulating tumor DNA in breast cancer may affect future treatment strategies.
EP. 8: Practical Advice on the Use of ctDNA Testing in Breast Cancer
Closing out their discussion on circulating tumor DNA in breast cancer management, experts share closing advice on practical strategies to use testing in clinic.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management
TERZO Trial Seeks to Validate Duvelisib as an Effective Targeted Treatment in TFH Nodal T-Cell Lymphoma
Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC
Kimberly Stegmaier Named as Pediatric Oncology Chair at Dana-Farber